AIM: To assess the clinical, biochemical and virological long-term outcome in chronic hepatitis C (CHC) patients with a sustained virological response (SVR) after peginterferon (PEG-IFN) plus ribavirin combination therapy. METHODS: One hundred and fifty three patients with a SVR after treatment with PEG-IFN plus ribavirin were included in a 5-year follow-up study in a single Spanish center, based on standard clinical practice. Clinical anamnesis, biochemical analysis, hepatitis C virus RNA and alpha-fetoprotein measurement, ultrasonography and transient elastography were performed annually. RESULTS: The mean follow-up period of the 153 patients was 76 ± 13 mo after they obtained a SVR. Five patients (3.26%) presented with cirrhosis before treatment and 116 (75.8%) had genotype 1. No patient showed evidence of hepatic decompensation. One patient (0.65%) developed a hepatocellular carcinoma at month 30 after achieving SVR. There were no virological relapses during this follow-up period. Persistently elevated alanine aminotransferase was found in only one patient (0.65%). At the end of the 5-year follow-up, the mean value of transient elastography was 7 ± 4.3 kPa (F1). There were no deaths and no other tumors. CONCLUSION: The long-term outcome of 153 CHC patients with SVR to PEG-IFN plus ribavirin was good. No evidence of a virological relapse was seen. One patient (0.65%) developed a hepatocellular carcinoma.
AIM: To assess the clinical, biochemical and virological long-term outcome in chronic hepatitis C (CHC) patients with a sustained virological response (SVR) after peginterferon (PEG-IFN) plus ribavirin combination therapy. METHODS: One hundred and fifty three patients with a SVR after treatment with PEG-IFN plus ribavirin were included in a 5-year follow-up study in a single Spanish center, based on standard clinical practice. Clinical anamnesis, biochemical analysis, hepatitis C virus RNA and alpha-fetoprotein measurement, ultrasonography and transient elastography were performed annually. RESULTS: The mean follow-up period of the 153 patients was 76 ± 13 mo after they obtained a SVR. Five patients (3.26%) presented with cirrhosis before treatment and 116 (75.8%) had genotype 1. No patient showed evidence of hepatic decompensation. One patient (0.65%) developed a hepatocellular carcinoma at month 30 after achieving SVR. There were no virological relapses during this follow-up period. Persistently elevated alanine aminotransferase was found in only one patient (0.65%). At the end of the 5-year follow-up, the mean value of transient elastography was 7 ± 4.3 kPa (F1). There were no deaths and no other tumors. CONCLUSION: The long-term outcome of 153 CHCpatients with SVR to PEG-IFN plus ribavirin was good. No evidence of a virological relapse was seen. One patient (0.65%) developed a hepatocellular carcinoma.
Authors: A Kasahara; N Hayashi; K Mochizuki; M Takayanagi; K Yoshioka; S Kakumu; A Iijima; A Urushihara; K Kiyosawa; M Okuda; K Hino; K Okita Journal: Hepatology Date: 1998-05 Impact factor: 17.425
Authors: G Saracco; F Rosina; M L Abate; L Chiandussi; V Gallo; E Cerutti; A Di Napoli; A Solinas; A Deplano; A Tocco Journal: Hepatology Date: 1993-12 Impact factor: 17.425
Authors: C Cammà; V Di Marco; O Lo Iacono; P Almasio; M Giunta; P Fuschi; A Vaccaro; C Fabiano; S Magrin; R Di Stefano; C Bonura; L Pagliaro; A Craxì Journal: J Hepatol Date: 1998-04 Impact factor: 25.083
Authors: P Marcellin; N Boyer; A Gervais; M Martinot; M Pouteau; C Castelnau; A Kilani; J Areias; A Auperin; J P Benhamou; C Degott; S Erlinger Journal: Ann Intern Med Date: 1997-11-15 Impact factor: 25.391
Authors: B J Veldt; G Saracco; N Boyer; C Cammà; A Bellobuono; U Hopf; I Castillo; O Weiland; F Nevens; B E Hansen; S W Schalm Journal: Gut Date: 2004-10 Impact factor: 23.059
Authors: J G McHutchison; S C Gordon; E R Schiff; M L Shiffman; W M Lee; V K Rustgi; Z D Goodman; M H Ling; S Cort; J K Albrecht Journal: N Engl J Med Date: 1998-11-19 Impact factor: 91.245
Authors: Y Imai; S Kawata; S Tamura; I Yabuuchi; S Noda; M Inada; Y Maeda; Y Shirai; T Fukuzaki; I Kaji; H Ishikawa; Y Matsuda; M Nishikawa; K Seki; Y Matsuzawa Journal: Ann Intern Med Date: 1998-07-15 Impact factor: 25.391
Authors: José A Agúndez; Elena García-Martin; María L Maestro; Francisca Cuenca; Carmen Martínez; Luis Ortega; Miguel Carballo; Marta Vidaurreta; Marta Agreda; Gabriela Díaz-Zelaya; Avelina Suárez; Manuel Díaz-Rubio; José M Ladero Journal: PLoS One Date: 2012-05-29 Impact factor: 3.240